A Phase 3 Randomized, Open-label Study Comparing the Bria-IMT regimen in combination with Check Point Inhibitor vs Physician’s Choice in Metastatic Breast Cancer (BRIA-ABC)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
BriaCell Therapeutics
The purpose of this research study is to assess the safety and effectiveness of an experimental therapy for advanced breast cancer called Bria-IMT (SV-BR-1-GM) in combination with the immune checkpoint inhibitor, Retifanlimab (Zynyz). In this study, we want to see whether SV-BR-1-GM injections help boost your immune system and/or help control or help shrink your cancer along with the other drugs that also boost the immune system. The researchers will also be studying the safety of the SV-BR-1-GM in combination with the other drugs to investigate what effects (good and/or bad) the injections have on you and cancer.
Enrollment Form
This study is currently enrolling.